← Ginkgo Bioworks Holdings, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($119.9m) | ($126.7m) | ($1.8b) | ($2.1b) | ($892.9m) | ($547.0m) | ($312.8m) | — | |
| Depreciation and amortization | $10.8m | $13.9m | $29.1m | $42.6m | $70.5m | $63.0m | $59.0m | $54.0m | |
| Deferred income tax benefit | — | $0 | $0 | ($14.6m) | ($801k) | ($936k) | ($1.4m) | ($1.4m) | |
| Stock-based compensation | $771k | $476k | $1.6b | $1.9b | $229.9m | $112.3m | $81.5m | $68.8m | |
| Goodwill impairment | — | — | — | $0 | $0 | $47.9m | $0 | $0 | |
| Restructuring related impairment charges | — | — | — | $0 | $0 | $4.8m | $0 | — | |
| Impairment of long-lived assets | — | — | $0 | $0 | $121.4m | $5.8m | $0 | — | |
| Loss on equity method investments | $27.5m | $396k | $77.3m | $43.8m | $2.6m | $0 | $0 | — | |
| Accounts receivable ($357, $156 and $816 from related parties) | ($1.8m) | ($14.2m) | ($114.1m) | $55.0m | $50.1m | ($4.7m) | ($1.5m) | ($200k) | |
| Accounts payable | $664k | $7.0m | ($2.2m) | ($10.8m) | ($1.2m) | $4.8m | ($3.0m) | ($3.0m) | |
| Accrued expenses and other current liabilities | $4.2m | $8.7m | $44.8m | ($39.6m) | $16.9m | ($40.4m) | $10.4m | — | |
| Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties) | $4.9m | ($19.4m) | ($10.5m) | ($36.4m) | ($35.9m) | ($68.6m) | ($32.4m) | — | |
| Prepaid expenses and other current assets | ($4.0m) | ($11.4m) | ($3.0m) | ($8.7m) | $10.5m | $10.1m | ($5.2m) | — | |
| Other | — | $0 | $0 | ($439k) | ($990k) | $538k | $50k | — | |
| Net cash used in operating activities | ($44.7m) |
($135.8m)
-204.12%
|
($253.8m)
-86.86%
|
($252.2m)
+0.64%
|
($295.5m)
-17.17%
|
($319.6m)
-8.15%
|
($171.1m)
+46.47%
|
($178.4m)
-4.27%
|
|
| Loss on disposal of equipment | — | $0 | $0 | $3.1m | $842k | $844k | $0 | — | |
| Purchases of property and equipment | ($22.2m) | ($57.8m) | ($56.5m) | ($52.3m) | ($40.8m) | ($62.5m) | ($7.7m) | ($4.6m) | |
| Proceeds from sale of equipment | — | — | $0 | $0 | $4.4m | $648k | $574k | — | |
| Loss on investments | $27.2m | $3.7m | $11.5m | $53.3m | $54.8m | $28.8m | $16.4m | — | |
| Accretion of discount on marketable securities | — | — | — | — | $0 | $0 | ($3.4m) | — | |
| Purchases of marketable debt securities | — | — | — | — | $0 | $0 | ($418.6m) | — | |
| Maturities of marketable debt securities | — | — | — | — | $0 | $0 | $159.5m | — | |
| Proceeds from sale of marketable debt securities | — | — | — | — | $0 | $0 | $25.9m | — | |
| Business acquisitions, net of cash acquired | — | $0 | ($12.0m) | $82.4m | $0 | ($5.4m) | $0 | — | |
| Net cash used in investing activities | ($74.6m) | ($67.1m) | ($73.3m) | ($67.4m) | ($80.7m) | ($62.2m) | ($240.3m) | $56.5m | |
| Taxes paid related to net share settlement of equity awards | $31k | $0 | ($9.5m) | ($981k) | ($23k) | $0 | $0 | — | |
| Net cash provided by (used in) financing activities | $410.4m |
$90.3m
-77.99%
|
$1.5b
+1598.60%
|
$95.3m
-93.79%
|
($3.2m)
-103.37%
|
($1.7m)
+45.93%
|
$17.8m
+1122.14%
|
$34.5m
+94.37%
|
|
| Cash and cash equivalents, beginning of year | $495.3m | $380.8m | $1.6b | $1.3b | $944.1m | $561.6m | $167.2m | — | |
| Restricted cash, beginning of year | — | $5.1m | $42.9m | $53.8m | $45.5m | $44.2m | $45.2m | — | |
| Cash, cash equivalents and restricted cash, beginning of year | $498.5m | $385.9m | $1.6b | $1.4b | $989.6m | $605.7m | $212.4m | — | |
| Net decrease in cash, cash equivalents and restricted cash | $291.1m | ($112.6m) | $1.2b | ($223.3m) | ($380.0m) | ($383.8m) | ($393.4m) | — | |
| Effect of foreign exchange rates on cash and cash equivalents | — | $0 | ($19k) | $908k | ($588k) | ($281k) | $201k | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Non-cash customer consideration | — | $0 | ($24.2m) | ($34.3m) | ($1.4m) | ($1.1m) | $0 | — | |
| Change in fair value of notes receivable | ($914k) | ($1.1m) | $3.5m | ($3.8m) | $2.4m | $2.0m | $5.7m | — | |
| Change in fair value of warrant liabilities | $0 | $0 | ($58.6m) | ($125.0m) | ($5.2m) | ($5.7m) | $0 | — | |
| Change in fair value of contingent consideration liability | — | — | $293k | $1.3m | ($9.2m) | $3.2m | ($4.2m) | — | |
| Loss on deconsolidation of subsidiaries | — | $0 | $0 | ($31.9m) | $42.5m | $7.0m | $0 | — | |
| Non-cash lease expense | — | — | — | $19.1m | $28.3m | $28.1m | $30.1m | — | |
| Non-cash in-process research and development | — | — | $0 | $1.2m | $9.2m | $19.8m | $0 | — | |
| Other non-cash activity | ($728k) | $0 | ($270k) | $183k | $2.1m | $1.2m | $2.1m | — | |
| Operating lease right-of-use assets | — | $0 | $0 | $13.2m | $9.3m | $23.5m | $3.8m | — | |
| Other non-current assets | ($2.4m) | $1.8m | ($539k) | $921k | $2.6m | ($1.4m) | $296k | — | |
| Operating lease liabilities, current and non-current | — | $0 | $0 | ($10.8m) | ($22.8m) | ($14.9m) | ($27.9m) | — | |
| Other non-current liabilities | — | $2.7m | $18.6m | $31k | $452k | $2.1m | $11.5m | — | |
| Deconsolidation of subsidiaries - cash | — | $0 | $0 | ($55.7m) | ($43.0m) | $0 | $0 | — | |
| Purchases of notes receivable | — | ($10.1m) | $0 | ($40.0m) | $350k | $0 | $0 | — | |
| Proceeds from sales of marketable equity securities | — | — | — | $0 | $0 | $4.5m | $0 | — | |
| Proceeds from ATM offering | — | — | — | — | $0 | $0 | $19.5m | — | |
| Payment of issuance costs related to ATM offering | — | — | — | — | $0 | $0 | ($1.3m) | — | |
| Proceeds from exercise of stock options | $7k | $26k | $167k | $240k | $93k | $84k | $0 | — | |
| Principal payments on finance leases | — | — | ($1.1m) | ($1.2m) | ($1.3m) | ($897k) | ($354k) | — | |
| Contingent consideration payment | — | $0 | $0 | ($521k) | $1.4m | ($922k) | $0 | — | |
| Payment of equity issuance costs and other | — | — | — | ($1.5m) | ($580k) | ($4k) | $0 | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.